The role of liposomes in clinical nanomedicine development. What now? Now what?

The rapid rise in interest in 'nanomedicines' in the academic world over the last twenty years and the claims of success led to calls for reflection. The main body of text of this Commentary will be on answering the question: 'where to go with nanomedicines'? Research priorities for the future will be outlined based on experience with the most successful nanomedicines family within the broad field of nanomedicine so far: liposomes. An analysis of currently clinically tested, approved and marketed liposome-drug combinations provide these insights.

[1]  Robert J. Lee,et al.  Clinical translation of immunoliposomes for cancer therapy: recent perspectives , 2018, Expert opinion on drug delivery.

[2]  Shyam Sundar,et al.  Single-dose liposomal amphotericin B for visceral leishmaniasis in India. , 2010, The New England journal of medicine.

[3]  D. Richardson,et al.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come , 2016, Pharmacological Reviews.

[4]  S. Alzghari,et al.  Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. van der Meel,et al.  Translating nanomedicines: Thinking beyond materials? A young investigator's reply to 'The Novelty Bubble'. , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Robert K. Stuart,et al.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Li-Feng Hsu,et al.  A statistical analysis to assess the most critical bioequivalence parameters for generic liposomal products. , 2014, International journal of clinical pharmacology and therapeutics.

[8]  Kinam Park.  The beginning of the end of the nanomedicine hype. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[9]  V. Gebski,et al.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Sorenson,et al.  Liposomal Bupivacaine: A Review and Applications to Dermatologic Surgery , 2018, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[11]  R. Ihejirika,et al.  Efficacy of liposomal bupivacaine in shoulder surgery: a systematic review and meta-analysis. , 2019, Journal of shoulder and elbow surgery.

[12]  Ting Wang,et al.  Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization , 2019, Journal of Controlled Release.

[13]  Fabian Kiessling,et al.  Cancer nanomedicine: Is targeting our target? , 2016, Nature reviews. Materials.

[14]  G. Jensen,et al.  Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products , 2007, Antimicrobial Agents and Chemotherapy.

[15]  Gert Storm,et al.  Liposomes: The Science and the Regulatory Landscape , 2015 .

[16]  J. Leroux.  The novelty bubble , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[17]  G. Storm,et al.  Towards clinical translation of ligand‐functionalized liposomes in targeted cancer therapy: Challenges and opportunities , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Tracy K. Pettinger,et al.  Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.

[19]  Kinam Park.  The drug delivery field at the inflection point: Time to fight its way out of the egg , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[20]  A. Didierlaurent,et al.  Adjuvant system AS01: helping to overcome the challenges of modern vaccines , 2017, Expert review of vaccines.

[21]  P. Grodzinski.  NCI Cancer Nanotechnology Centers of Excellence (CCNEs) - A full story to set the record straight. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[22]  H. E. Meyer zu Schwabedissen,et al.  Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide , 2019, eLife.

[23]  M. Saif,et al.  Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer , 2017, Therapeutic advances in gastroenterology.

[24]  F. Kiessling,et al.  Personalized Nanomedicine , 2012, Clinical Cancer Research.

[25]  Leaf Huang,et al.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. , 2012, Vaccine.

[26]  F. Danhier,et al.  To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Celia N. Cruz,et al.  The evolving landscape of drug products containing nanomaterials in the United States. , 2017, Nature nanotechnology.

[28]  C. Moonen,et al.  Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. , 2017, Advanced drug delivery reviews.

[29]  E. D. de Melo,et al.  Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial , 2017, PLoS neglected tropical diseases.

[30]  R. Rifkin,et al.  Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma , 2006, Cancer.

[31]  F. Kiessling,et al.  Physicochemical and biological aspects of macrophage‐mediated drug targeting in anti‐microbial therapy , 2012, Fundamental & clinical pharmacology.

[32]  Mi-Kyung Lee.  Clinical usefulness of liposomal formulations in cancer therapy: lessons from the experiences of doxorubicin , 2018, Journal of Pharmaceutical Investigation.

[33]  T. Vedvick,et al.  Working together: interactions between vaccine antigens and adjuvants , 2013, Therapeutic advances in vaccines.

[34]  J. Adler-Moore,et al.  Comparison between liposomal formulations of amphotericin B. , 2016, Medical mycology.

[35]  S. Sundar,et al.  Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial , 2011, The Lancet.